Biogaia AB
F:BGLA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Biogaia AB
F:BGLA
|
SE |
|
Qualys Inc
NASDAQ:QLYS
|
US |
|
C
|
Cartesian Therapeutics Inc
SWB:1S7
|
US |
|
Ryanair Holdings PLC
NASDAQ:RYAAY
|
IE |
|
Air China Ltd
SSE:601111
|
CN |
|
Finnair Oyj
F:FAI0
|
FI |
|
S
|
Schnitzer Steel Industries Inc
F:SS1A
|
US |
|
S
|
Shangri-La Asia Ltd
XMUN:SHN
|
HK |
|
M
|
Micron Technology Inc
F:MTE
|
US |
|
Blue Bird Corp
F:4RB
|
US |
|
Axway Software SA
F:1XV
|
FR |
|
Y
|
Yangarra Resources Ltd
F:702B
|
CA |
|
C
|
Conagra Brands Inc
SWB:CAO
|
US |
|
V
|
Vardhman Textiles Ltd
BSE:502986
|
IN |
|
Broadcom Inc
SIX:AVGO
|
US |
|
K
|
Katek Se
XHAM:KTE
|
DE |
|
A
|
Alcoa Corp
F:185
|
US |
|
N
|
Neurocrine Biosciences Inc
SWB:NB3
|
US |
|
Mullen Group Ltd
TSX:MTL
|
CA |
|
B
|
Basler AG
XHAM:BSL
|
DE |
|
Cbrain A/S
F:C6F
|
DK |
|
I
|
Indika Energy Tbk PT
SWB:I41
|
ID |
|
P
|
Peloton Interactive Inc
F:2ON
|
US |
|
B
|
Booking Holdings Inc
XMUN:PCE1
|
US |
Biogaia AB
BioGaia AB is a Swedish health company that develops and sells probiotic products, mainly based on carefully selected live bacteria strains. Its products are sold as drops, tablets, capsules, and other oral or digestive health products that are used to support the gut, immune system, and general well-being. The company also develops related medical and nutrition products built around its probiotic research. BioGaia sells to consumers through pharmacies, health stores, and online channels, and it also works with distributors, healthcare professionals, and food or supplement partners in many markets. It makes money by licensing its probiotic strains, selling finished consumer products, and earning royalties and product sales through partner brands and distribution agreements. What makes BioGaia different is that it sits between scientific research and consumer health products. Rather than being a broad drugmaker, it focuses on a narrow area: probiotics backed by strain-specific research and branded products that can be sold through healthcare and retail channels. That gives it a business model built around intellectual property, partnerships, and recurring demand for everyday wellness products.
BioGaia AB is a Swedish health company that develops and sells probiotic products, mainly based on carefully selected live bacteria strains. Its products are sold as drops, tablets, capsules, and other oral or digestive health products that are used to support the gut, immune system, and general well-being. The company also develops related medical and nutrition products built around its probiotic research.
BioGaia sells to consumers through pharmacies, health stores, and online channels, and it also works with distributors, healthcare professionals, and food or supplement partners in many markets. It makes money by licensing its probiotic strains, selling finished consumer products, and earning royalties and product sales through partner brands and distribution agreements.
What makes BioGaia different is that it sits between scientific research and consumer health products. Rather than being a broad drugmaker, it focuses on a narrow area: probiotics backed by strain-specific research and branded products that can be sold through healthcare and retail channels. That gives it a business model built around intellectual property, partnerships, and recurring demand for everyday wellness products.
Strong Sales Growth: BioGaia reported Q4 sales of SEK 365 million, up 23% year-on-year, with regional growth led by the Americas (+32%), EMEA (+24%), and Asia Pacific (+10%).
Profitability: Operating profit (EBIT) grew 28% to SEK 103 million, with an EBIT margin of 28% for the quarter.
Gross Margin Decline: Gross margin dropped to 71% from 76% last year, with Pediatrics especially impacted due to inventory write-downs and sales mix.
Dividend Proposal: Board proposed a total dividend of SEK 6.90 per share, totaling SEK 698 million.
Product Launches: New products included BioGaia Gastrus PURE ACTION and expanded launches in several markets.
Direct Sales Strategy: BioGaia is increasing direct market operations, including plans to take French distribution in-house.
Market Outperformance: Quarterly results exceeded market expectations.
